MX2018004930A - Peptidos. - Google Patents
Peptidos.Info
- Publication number
- MX2018004930A MX2018004930A MX2018004930A MX2018004930A MX2018004930A MX 2018004930 A MX2018004930 A MX 2018004930A MX 2018004930 A MX2018004930 A MX 2018004930A MX 2018004930 A MX2018004930 A MX 2018004930A MX 2018004930 A MX2018004930 A MX 2018004930A
- Authority
- MX
- Mexico
- Prior art keywords
- amino acid
- absent
- side chain
- amino acids
- peptide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 235000001014 amino acid Nutrition 0.000 abstract 9
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 7
- 150000001413 amino acids Chemical class 0.000 abstract 4
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229920006317 cationic polymer Polymers 0.000 abstract 1
- 230000032823 cell division Effects 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1518700.8A GB2543550A (en) | 2015-10-21 | 2015-10-21 | Peptides |
| PCT/GB2016/053282 WO2017068353A1 (en) | 2015-10-21 | 2016-10-20 | Peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018004930A true MX2018004930A (es) | 2018-11-09 |
Family
ID=55131441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018004930A MX2018004930A (es) | 2015-10-21 | 2016-10-20 | Peptidos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10494412B2 (enExample) |
| EP (2) | EP3364992B1 (enExample) |
| JP (1) | JP2018533570A (enExample) |
| KR (1) | KR20180080217A (enExample) |
| CN (1) | CN108430491A (enExample) |
| AU (1) | AU2016341494A1 (enExample) |
| BR (1) | BR112018008136A2 (enExample) |
| CA (1) | CA3002739A1 (enExample) |
| EA (1) | EA201890900A1 (enExample) |
| ES (1) | ES2775740T3 (enExample) |
| GB (1) | GB2543550A (enExample) |
| MX (1) | MX2018004930A (enExample) |
| WO (1) | WO2017068353A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121287874B (zh) * | 2025-12-12 | 2026-03-17 | 广州飞来爱生命科技有限公司 | 一种治疗前列腺疾病的间充质干细胞组合物及其制备方法和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| ATE291230T1 (de) * | 1994-01-14 | 2005-04-15 | Matthias Dr Med Rath | Verwendung von methoden zur identifizierung von hydrophilen signal-oligopeptiden |
| US5608082A (en) | 1994-07-28 | 1997-03-04 | Agouron Pharmaceuticals, Inc. | Compounds useful as antiproliferative agents and GARFT inhibitors |
| UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| HRP20020751B1 (hr) | 2000-02-15 | 2011-01-31 | Sugen | Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze |
| NZ527302A (en) | 2001-01-05 | 2006-10-27 | Abgenix Inc | Antibodies to insulin-like growth factor I receptor |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| PA8580301A1 (es) | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
| GB0229151D0 (en) * | 2002-12-13 | 2003-01-15 | St Georges Entpr Ltd | Product and method |
| US7259266B2 (en) | 2003-03-31 | 2007-08-21 | Pharmacia Corporation | Benzopyran compounds useful for treating inflammatory conditions |
| US20050148627A1 (en) | 2003-03-31 | 2005-07-07 | Jeffery Carter | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions |
| EP1909811B1 (en) * | 2005-06-29 | 2012-02-01 | St. George's Enterprises Limited | Hox peptides as pbx modulators for the treatment of cancer |
| US7928186B2 (en) * | 2006-08-02 | 2011-04-19 | Phoenix Pharmaceuticals, Inc. | Cell permeable bioactive peptide conjugates |
| WO2009094634A1 (en) * | 2008-01-24 | 2009-07-30 | Esperance Pharmaceuticals | Lytic domain fusion constructs and methods of making and using same |
| JP6943759B2 (ja) | 2017-12-28 | 2021-10-06 | 株式会社東海理化電機製作所 | シフト装置 |
-
2015
- 2015-10-21 GB GB1518700.8A patent/GB2543550A/en not_active Withdrawn
-
2016
- 2016-10-20 CN CN201680074733.7A patent/CN108430491A/zh active Pending
- 2016-10-20 AU AU2016341494A patent/AU2016341494A1/en not_active Abandoned
- 2016-10-20 KR KR1020187012506A patent/KR20180080217A/ko not_active Withdrawn
- 2016-10-20 CA CA3002739A patent/CA3002739A1/en not_active Abandoned
- 2016-10-20 EP EP16801003.1A patent/EP3364992B1/en active Active
- 2016-10-20 ES ES16801003T patent/ES2775740T3/es active Active
- 2016-10-20 EA EA201890900A patent/EA201890900A1/ru unknown
- 2016-10-20 US US15/770,023 patent/US10494412B2/en active Active
- 2016-10-20 MX MX2018004930A patent/MX2018004930A/es unknown
- 2016-10-20 JP JP2018520389A patent/JP2018533570A/ja active Pending
- 2016-10-20 WO PCT/GB2016/053282 patent/WO2017068353A1/en not_active Ceased
- 2016-10-20 BR BR112018008136A patent/BR112018008136A2/pt not_active Application Discontinuation
- 2016-10-20 EP EP19200535.3A patent/EP3610883A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180080217A (ko) | 2018-07-11 |
| CA3002739A1 (en) | 2017-04-27 |
| CN108430491A (zh) | 2018-08-21 |
| BR112018008136A2 (pt) | 2018-11-06 |
| US10494412B2 (en) | 2019-12-03 |
| WO2017068353A1 (en) | 2017-04-27 |
| ES2775740T3 (es) | 2020-07-28 |
| ES2775740T8 (es) | 2020-08-06 |
| EA201890900A1 (ru) | 2018-10-31 |
| AU2016341494A1 (en) | 2018-05-24 |
| GB2543550A (en) | 2017-04-26 |
| EP3610883A1 (en) | 2020-02-19 |
| GB201518700D0 (en) | 2015-12-02 |
| US20180282384A1 (en) | 2018-10-04 |
| EP3364992A1 (en) | 2018-08-29 |
| JP2018533570A (ja) | 2018-11-15 |
| EP3364992B1 (en) | 2019-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012001075A3 (en) | Immortalized avian cell lines | |
| PH12018501055A1 (en) | Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders | |
| EP3936141A3 (en) | Anti-senescence compounds and uses thereof | |
| EP4230644A3 (en) | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate | |
| UA118167C2 (uk) | Пептид та його застосування | |
| MY172292A (en) | Vectors and sequences for the treatment of diseases | |
| MX2012009748A (es) | USO DE PEPTIDOS INHIBIDORES DEL FACTOR DE CRECIMIENTO TRANSFORMANTE-BETA1(TGF-ß1) PARA EL TRATAMIENTO DE FIBROSIS Y/U OPACIDAD CORNEAL. | |
| EP3760713A3 (en) | Lipase variants and polynucleotides encoding same | |
| WO2012054356A3 (en) | Cross connectors | |
| EP3950939A3 (en) | Lipase variants and polynucleotides encoding same | |
| WO2018215525A8 (en) | Mic-1 compounds and uses thereof | |
| PH12018500155A1 (en) | Recombinant orf virus vector | |
| PH12021551428A1 (en) | Recombinant avian herpes viruses containing multiple foreign genes | |
| MX2017016227A (es) | Peptidos anti-infecciosos de amplio espectro. | |
| EP2988359A3 (en) | Anodes for use in biocompatible energization elements | |
| EP4275750A3 (en) | Treatment of alzheimer's disease in a particular patient population | |
| PH12018502133A1 (en) | Conjugated c1 esterase inhibitor and uses thereof | |
| WO2016094829A8 (en) | Self-assembling peptides comprising non-ionic polar amino acids | |
| EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
| WO2011123858A3 (en) | Ccn3 peptides and analogs thereof for therapeutic use | |
| WO2016172269A3 (en) | Insulin analogs having shortened b chain peptides and associated methods | |
| EP4282960A3 (en) | Modified lipase and use thereof | |
| ATE506373T1 (de) | Peptide, welche die pbx abhängige genregulation beeinträchtigen | |
| EA201890900A1 (ru) | Пептиды | |
| WO2016085279A3 (ko) | 세포 투과 펩타이드-면역조절제 접합체 및 이를 포함하는 면역질환 치료용 조성물 |